Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May;63(5):720–726. doi: 10.2967/jnumed.121.262485

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the Society of Nuclear Medicine and Molecular Imaging.

Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

PMC Copyright notice

FIGURE 1. — Serum clearance and biodistribution of ⁸⁹Zr-Df-IAB22M2C. (A) Serum clearance of ⁸⁹Zr-Df-IAB22M2C based on enzyme-linked immunosorbent assay measurements (limit of detection = 5 ng/mL). No minibody was detected in serum at the 0.2-mg dose. (B) Whole-body PET images of a patient at various times after injection of ⁸⁹Zr-Df-IAB22M2C (1.5-mg minibody dose) demonstrating the distribution of ⁸⁹Zr-Df-IAB22M2C in normal tissues and uptake in a nodal metastasis in the right neck (arrow), with good visualization of uptake in the nodal metastasis at 24–48 h after injection.